{"release":"wpf-claim-checks","version":"1.0.0","checkedOn":"2026-11-13","verificationLabel":"AI-assisted source verification","humanReview":"none recorded","claim":{"id":"tirzepatide-semaglutide-same-trial","question":"Were tirzepatide and semaglutide compared in the same trial?","answer":"Yes, in SURMOUNT-5, a 72-week open-label trial in adults with obesity. Other weight-loss results for the two drugs come from separate trials and cannot be subtracted from each other.","verdict":"yes_in_one_trial","supported":["SURMOUNT-5 (phase 3b, open-label) randomized 751 adults with obesity, without type 2 diabetes to tirzepatide vs semaglutide.","Result: -20.2% with tirzepatide vs -13.7% with semaglutide (least-squares means; P<0.001). Uncertainty: 95% CI -21.4 to -19.1 (tirzepatide); -14.9 to -12.6 (semaglutide).","The registry record NCT05822830 lists the study as completed with results posted."],"uncertain":["The trial was open-label, so participants and investigators knew which drug they received.","The publication abstract does not name the estimand. WPF matched the displayed values to the analysis plan by method, not by an explicit label.","STEP 1 and SURMOUNT-1 are separate placebo-controlled trials. Their percentages describe different populations and designs, so the gap between them is not a head-to-head result."],"checkedOn":"2026-11-13","sources":[{"label":"ClinicalTrials.gov NCT05822830","url":"https://clinicaltrials.gov/study/NCT05822830"},{"label":"Publication doi:10.1056/NEJMoa2416394 (PMID 40353578)","url":"https://doi.org/10.1056/NEJMoa2416394"}],"underlying":[{"label":"Flagship Weight Management 1.3.0, result surmount-5-weight-72w","url":"https://www.worldpeptidefoundation.org/api/research/flagship/weight-management?version=1.3.0&resultId=surmount-5-weight-72w"}],"record":{"label":"This claim check, version 1.0.0","url":"https://www.worldpeptidefoundation.org/api/research/claims/tirzepatide-semaglutide-same-trial?version=1.0.0"},"journey":{"label":"Semaglutide research journey","url":"https://www.worldpeptidefoundation.org/research/journey/semaglutide#result"},"citation":"Were tirzepatide and semaglutide compared in the same trial? Yes, in SURMOUNT-5, a 72-week open-label trial in adults with obesity. Other weight-loss results for the two drugs come from separate trials and cannot be subtracted from each other. Cited from World Peptide Foundation, Check a claim, version 1.0.0, claim tirzepatide-semaglutide-same-trial, checked 2026-11-13. Versioned record: https://www.worldpeptidefoundation.org/api/research/claims/tirzepatide-semaglutide-same-trial?version=1.0.0. Page: https://www.worldpeptidefoundation.org/research/check#tirzepatide-semaglutide-same-trial. AI-assisted source verification; human review none recorded."},"sha256":"75e119bde33c2cab495bde11420b5b3960569f82dc22046c83051add9f698a3c"}